Skip to main content
SpringerLink
Log in

The β3-Adrenergic System and β3-Adrenergic Agonists

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Arch JRS, Piercy V, Thurlby PL, Wilson C, Wilson S. Thermogenic and lipolytic drugs for the treatment of obesity: old ideas and new possibilities. In: Berry EM, Blondheim SH, Eliahou HE, Shafrir E, eds. Recent Advances in Obesity Research. V edn. London: John Libbey, 1987;300-311.

    Google Scholar 

  2. Schiffelers SLH, van Harmelen VJA, de Grauw HAJ, Saris WHM, van Baak MA. Dobutamine as selective β1adrenoceptor agonist in in vivo studies on human thermogenesis and lipid utilization. J Appl Physiol 1999;87:977-981.

    Google Scholar 

  3. Amoroso P, Wilson SR, Moxham J, Ponte J. Acute effects of inhaled salbutamol on the metabolic rate of normal subjects. Thorax 1993;48:882-885.

    Google Scholar 

  4. Cawthorne MA, Arch JRS. The search for peripherally acting drugs for the treatment of obesity--a review. Int J Obesity 1982;6:1-10.

    Google Scholar 

  5. Astrup A, Breum L, Toubro S, Hein P, Quade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: A double blind trial. Int J Obesity 1992;16:269-277.

    Google Scholar 

  6. Norregaard J, Jorgensen S, Mikkelsen KL, Tonnesen P, Iversen E, Sorensen T, Soeberg B, Jakobsen HB. The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain. Clin Pharm Ther 1996;60:679-686.

    Google Scholar 

  7. Holloway BR. Selective β-agonists of brown fat and thermogenesis. In: Lardy HA, Stratman FW, eds. Hormones, Thermogenesis, and Obesity. Elsevier Science Publishing Co., Inc., 1989;477-484.

  8. Montastruc JL, Verwaerde P, Pelat M, Galitzky J, Langin D, Lafontan M, Berlan M. Peripheral cardiovascular actions of SR58611A, a β3-adrenoceptor agonist, in the dog: Lack of central effect. Fundament Clin Pharmacol 1999;13:180-186.

    Google Scholar 

  9. Shen Y-T, Cervoni P, Claus T, Vatner SF. Differences in β3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J Pharmacol Exp Ther 1996;278:1435-1443.

    Google Scholar 

  10. Hom GJ, Forrest MJ, Bach TJ, Brady E, Candelore MR, Cascieri MA, Fletcher DJ, Fisher MH, Iliff SA, Mathvink RJ, Metzger J, Pecore V, Saperstein R, Shih T, Weber AE, Wyrvratt M, Zafian P, MacIntyre DE. β3-Adrenoceptor agonist-induced increases in lipolysis, metabolic rate, facial flushing, and reflex tachycardia in anesthetized rhesus monkeys. J Pharmacol Exp Ther 2001;297:299-307.

    Google Scholar 

  11. Fisher MH, Amend AM, Bach TJ, Barker JM, Brady EJ, Candelore MR, Carroll D, Cascieri MA, Chiu S-HL, Deng L, Forrest MJ, Hegarty-Friscino B, Guan X-M, Hom GJ, Hutchins JE, Kelly LJ, Mathvink RJ, Metzger JM, Miller RR, Ok HO, Parmee ER, Saperstein R, Strader CD, Stearns RA, Thompson GM, Tota L, Vicario PP, Weber AE, Woods JW, Wyvratt MJ, Zafian PT, MacIntyre DE. A selective human β3 adrenergic receptor agonist increases metabolic rate in Rhesus monkeys. J Clin Invest 1998;101:2387-2393.

    Google Scholar 

  12. Foster DC, Frydman ML. Nonshivering thermogenesis in the rat. II Measurements of blood flow with microspheres point to brown adipose tissue as the dominant site of the calorigenesis induced by noradrenaline. Can J Physiol Pharmacol 1978;56:110-122.

    Google Scholar 

  13. Arch JRS, Ainsworth AT. Thermogenic and antiobesity activity of a novel β-adrenoceptor agonist (BRL 26830A) in mice and rats. Am J Clin Nutr 1983;38:549-558.

    Google Scholar 

  14. Arch JRS, Kaumann AJ. β3 and atypical β-adrenoceptors. Med Res Rev 1993;13:663-729.

    Google Scholar 

  15. Arch JRS, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S. Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984;309:163-165.

    Google Scholar 

  16. Wilson C, Wilson S, Piercy V, Sennitt MV, Arch JRS. The rat lipolytic β-adrenoceptor: Studies using novel β-adrenoceptor agonists. Eur J Pharmacol 1984;100:309-319.

    Google Scholar 

  17. Emorine LJ, Marullo S, Briend-Sutren M-M, Patey G, Tate T, Delavier-Klutchko C, Strosberg AD. Molecular characterisation of the human β3-adrenergic receptor. Science 1989;245:1118-1121.

    Google Scholar 

  18. Arch JRS. β3-adrenoceptor ligands and pharmacology of the β3-adrenoceptor. In: Strosberg AD, ed. The β3-Adrenoceptor. London & New York: Taylor & Francis, 2000;48-76.

    Google Scholar 

  19. Miller JW, Farid NA, Johnson RD, Smith BP, Dananberg J. Stimulation of energy expenditure by LY377604, a β3-adrenergic receptor agonist with β1/2-antagonist properties, in healthy male subjects. Obesity Res 1999;7:121S.

    Google Scholar 

  20. Kaumann AJ. Four β-adrenoceptor subtypes in the mammalian heart. Trends Pharmacol Sci 1997;18:70-76.

    Google Scholar 

  21. Galitzky J, Langin D, Verwaerde P, Montastruc JL, Lafontan M, Berlan M. Lipolytic effects of conventional β3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: Preliminary pharmacological evidence for a putative β4-adrenoceptor. Br J Pharmacol 1997;122:1244-1250.

    Google Scholar 

  22. Granneman JG. The putative β4-adrenergic receptor is a novel state of the β1-adrenergic receptor. Am J Physiol 2001;43:E199-E202.

    Google Scholar 

  23. Kaumann AJ, Engelhardt S, Hein L, Molenaar P, Lohse M. Abolition of ( − )-CGP 12177-evoked cardiostimulation in double β(1)/β(2)-adrenoceptor knockout mice. Obligatory role of β(1)-adrenoceptors for putative β4-adrenoceptor pharmacology. Naunyn-Schmiedeberg's Arch Pharmacol 2001;363:87-93.

    Google Scholar 

  24. Sennitt MV, Kaumann AJ, Molenaar P, Beeley LJ, Young PW, Kelly J, Chapman H, Henson SM, Berge JM, Dean DK, Kotecha NR, Morgan HKA, Rami HK, Ward RW, Thompson M, Wilson S, Smith SA, Cawthorne MA, Stock MJ, Arch JRS. The contribution of classical (β1/2-) and atypical adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel β3-adrenoceptor agonists of differing selectivities. J Pharmacol Exp Ther 1998;285:1084-1095.

    Google Scholar 

  25. Arch JRS, Kaumann AJ, Molenaar P, Sennitt MV, Berge JM, Chapman H, Kelly J. Studies on a novel selective β3-adrenoceptor agonist in human right atrial appendage and human white adipocytes. Br J Pharmacol 1999;126:100P.

    Google Scholar 

  26. Konkar AA, Zhu Z, Granneman JG. Aryloxypropanolamine and catecholamine ligand interactions with the β1-adrenergic receptor: Evidence for interaction with distinct conformations of β1-adrenergic receptors. J Pharmacol Exp Ther 2000;294:923-932.

    Google Scholar 

  27. Gavrilova O, Marcus-Samuels B, Reitman ML. Lack of responses to a β3-adrenergic agonist in lipoatrophic A-ZIP/F-1 mice. Diabetes 2000;49:1910-1916.

    Google Scholar 

  28. Tsujii S, Bray GA. A β-3 adrenergic agonist (BRL-37344) decreases food intake. Physiology & Behavior 1998;63:723-728.

    Google Scholar 

  29. Bray GA. Reciprocal relation of food intake and sympathetic activity: experimental observations and clinical implications. Int J Obesity 2000;24(Suppl. 2):S8-S17.

    Google Scholar 

  30. Igawa Y, Yamazaki Z, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, Yoneyama T, Nishizawa O, Andersson KE. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 1999;126:819-825.

    Google Scholar 

  31. Gauthier C, Langin D, Balligand J-L. β3-Adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 2000;21:426-431.

    Google Scholar 

  32. Thurlby PL, Ellis RDM. Differences between the effects of noradrenaline and the β-adrenoceptor agonist BRL 28410 in brown adipose tissue and hind limb of the anaesthetized rat. Can J Physiol Pharmacol 1986;64:1111-1114.

    Google Scholar 

  33. Lowell BB, Susulic VS, Hamann A, Lawitts JA, Himms-Hagen J, Boyer BB, Kozak LP, Flier JS. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 1993;366:740-742.

    Google Scholar 

  34. Lean MEJ, Trayhurn P, Murgatroyd PR, Dixon AK. The case for brown adipose tissue function in humans: biochemistry, physiology and computed tomography. In: Berry EM, Blondheim SH, Eliahou HE, Shaffrir E. Recent Advances in Obesity Research. V edn. London: John Libbey, 1987;110-117.

    Google Scholar 

  35. Blaak EE, van Baak MA, Kemerink GJ, Pakbiers MTW, Heidendal GAK, Saris WHM. β-adrenergic stimulation of energy expenditure and forearm skeletal muscle metabolism in lean and obese men. Am J Physiol 1994;267:E306-E315.

    Google Scholar 

  36. Block BA. Thermogenesis in muscle. Annu Rev Physiol 1994;56:535-577.

    Google Scholar 

  37. Astrup A, Bulow J, Madsen J, Christensen NJ. Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man. Am J Physiol 1985;248:E507-E515.

    Google Scholar 

  38. Havel RJ, Carlson LA, Ekelund L-G, Holmgren A. Studies on the relation between mobilization of free fatty acids and energy metabolism in man: effects of norepinephrine and nicotinic acid. Metabolism 1964;13:1402-1411.

    Google Scholar 

  39. Schiffelers SLH, Brouwer EMC, Saris WHM, van Baak MA. Inhibition of lipolysis reduces β1-adrenoceptor-mediated thermogenesis in man. Metabolism 1998;47:1462-1467.

    Google Scholar 

  40. Grujic D, Susulic VS, Harper M-E, Hims-Hagen J, Cunningham BA, Corkey BE, Lowell BB. β3-adrenergic receptors on white and brown adipocytes mediate β3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake. J Biol Chem 1997;272:17686-17693.

    Google Scholar 

  41. Wilson S, Thurlby PL, Arch JRS. Substrate supply for thermogenesis induced by the β-adrenoceptor agonist BRL 26830A. Can J Physiol Pharmacol 1986;65:113-119.

    Google Scholar 

  42. Ito M, Grujic D, Abel ED, Vidalpuig A, Susulic VS, Lawitts J, Harper ME, Himms-Hagen J, Strosberg AD, Lowell BB. Mice expressing human but not murine β-adrenergic receptors under the control of human gene regulatory elements. Diabetes 1998;47:1464-1471.

    Google Scholar 

  43. Evans BA, Papaioannou M, Bonazzi VR, Summers RJ. Expression of β3-adrenoceptor mRNA in rat tissues. Br J Pharmacol 1996;117:210-216.

    Google Scholar 

  44. Thomas RF, Liggett SB. Lack of β3-adrenergic receptor mRNA expression in adipose and other metabolic tissues in the adult human. Mol Pharmacol 1993;43:343-348.

    Google Scholar 

  45. Strosberg AD, Gerhardt CC. Structure and function of the β3-adrenoceptor. In: Strosberg AD, ed. The β3-Adrenoceptor. London & New York: Taylor & Francis, 2000;1-19.

    Google Scholar 

  46. Chamberlain PD, Jennings KH, Paul F, Cordell J, Berry A, Holmes SD, Park J, Sennitt MV, Stock MJ, Cawthorne MA, Young PW, Murphy GJ. The tissue distribution of the human β3-adrenoceptor studies using a monoclonal antibody. Int J Obesity 1999;23:1057-1065.

    Google Scholar 

  47. Onai T, Kilroy G, York DA, Bray GA. Regulation of β3-adrenergic receptor mRNA by sympathetic nerves and glucocorticoids in BAT of Zucker obese rats. Am J Physiol 1995;269:R519-R526.

    Google Scholar 

  48. Macdonald IA. Advances in our understanding of the role of the sympathetic nervous system in obesity. Int J Obes Relat Metab Disord 1995;19:S2-S7.

    Google Scholar 

  49. Hollenga C, Zaagsma J. Direct evidence for the atypical nature of functional β-adrenoceptors in rat adipocytes. Br J Pharmacol 1989;98:1420-1424.

    Google Scholar 

  50. Hoffstedt J, Lonnqvist F, Shimizu M, Black E, Arner P. Effects of several putative β3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obesity 1996;20:428-434.

    Google Scholar 

  51. Challis RAJ, Leighton B, Wilson S, Thurlby PL, Arch JRS. An investigation of the β-adrenoceptor that mediates metabolic responses to the novel agonist BRL 28410 in rat soleus muscle. Biochem Pharmacol 1988;37:947-950.

    Google Scholar 

  52. Allison DB, Heo M, Faith MS, Pietrobelli A. Meta-analysis of the association of the Trp64Arg polymorphism in the β3 adrenergic receptor with body mass index. Int J Obesity 1998;22:559-566.

    Google Scholar 

  53. Fujisawa T, Ikegami H, Kawaguchi Y, and Ogihara T. Meta-analysis of the association of Trp(64)Arg polymorphism of β3-adrenergic receptor gene with body mass index. J Clin Endocrinol Metab 1998;83:2441-2444.

    Google Scholar 

  54. Umekawa T, Yoshida T, Sakane N, Kogure A, Kondo M, Honjyo H. Trp64Arg mutation of β3-adrenoceptor gene deteriorates lipolysis induced by β3-adrenoceptor agonist in human omental adipocytes. Diabetes 1999;48:117-120.

    Google Scholar 

  55. Pietri-Rouxel F, Strosberg AD. Pharmacological characteristics and species-related variations of β3-adrenergic receptors. Fundament Clin Pharmacol 1995;9:211-218.

    Google Scholar 

  56. Wheeldon NM, McDevitt DG, Lipworth BJ. Do β3-adrenoceptors mediate metabolic responses to isoprenaline. Quart J Med 1993;86:595-600.

    Google Scholar 

  57. Liu Y-L, Toubro S, Astrup A, Stock MJ. Contribution of β3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obesity 1995;19:678-685.

    Google Scholar 

  58. Wheeldon NM, McDevitt DG, McFarlane LC, Lipworth BJ. β-adrenoceptor subtypes mediating the metabolic effects of BRL 35135 in man. Clin Sci 1994;86:331-337.

    Google Scholar 

  59. Schiffelers SLH, Blaak EE, Saris WHM, and van Baak MA. In vivo β3-adrenergic stimulation of human thermogenesis and lipid use. Clin Pharm Ther 2000;67:558-566.

    Google Scholar 

  60. van Baak MA, Hul G, Toubro S, Astrup A. Acute thermogenic effect of L-796568, a novel β3-adrenoceptor agonist, in obese men. Obesity Res 2000;8:91S.

    Google Scholar 

  61. Wilson S, Chambers JK, Park JE, Ladurner A, Cronk DW, Chapman CG, Kallender H, Browne MJ, Murphy GJ, Young PW. Agonist potency at the cloned human β3-adrenoceptor depends on receptor expression level and nature of the assay. J Pharmacol Exp Ther 1996;279:214-221.

    Google Scholar 

  62. Arch JRS. Subclassification of β-adrenoceptors: The pharmacology of β3-adrenoceptors in tissues. Pharmacol Commun 1995;6(1–3):223-228.

    Google Scholar 

  63. Arch JRS, Bywater RJ, Coney KA, Ellis RDM, Thurlby PL, Smith SA, Zed C. β-adrenoceptor-mediated control of thermogenesis, body composition and glucose homeostasis. In: Lardy H, Stratman F, eds. Hormones, Thermogenesis and Obesity. Amsterdam: Elsevier Science Publishing Co., 1995;465-476.

    Google Scholar 

  64. Abraham R, Zed C, Mitchell T, Parr J, Wynn V. The effect of a novel β-agonist BRL 26830A on weight and protein loss in obese patients. Int J Obesity 1987;11:306A.

    Google Scholar 

  65. Durrant ML, Garrow JS, Royston P, Stalley SF, Sunkin S, Warwick PM. Factors influencing the composition of the weight lost by obese patients on a reducing diet. Br J Nutrition 1980;44:275-285.

    Google Scholar 

  66. Kiso T, Namikawa T, Tokunaga T, Sawada K, Kakita T, Shagaki T, Ohtsubo Y. Anti-obesity and anti-diabetic activity of a new β3 adrenergic receptor agonist, (S)-(Z)-[4-[[1-[2-[(hydroxy-3-phenoxypropyl)]amino]ethyl]1-propenyl]phenoxy] acetic acid ethanedioic acid (SWR-0342SA), in KK-Ay mice. Biol Pharm Bull 1999;22:1073-1078.

    Google Scholar 

  67. Bryson JM, Wensley VR, Phuyal JL, Caterson ID, Cooney GJ. Chronic administration of BRL 26830A for 9 weeks improves insulin sensitivity but does not prevent weight gain in gold-thioglucose obese mice. Horm Metab Res 1999;31:317-322.

    Google Scholar 

  68. Hansen BC. Primates in the experimental pharmacology of obesity. In: Lockwood D, Heffner TG, eds. Handbook of Experimental Pharmacology. 149 edn. Heidelberg: Springer-Verlag, 2000;461-489.

    Google Scholar 

  69. Smith SA, Sennitt MV, Cawthorne MA. BRL 35135: an orally active antihyperglycaemic agent with weight reducing effects. In: Bailey CJ, Flatt PR eds. New Antidiabetic Drugs. London: Smith-Gordon, 1990;177-189.

    Google Scholar 

  70. Weyer C, Tataranni A, Snitker S, Danforth EJ, Ravussin E. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective β3-adrenoceptor agonist in humans. Diabetes 1998;47:1555-1561.

    Google Scholar 

  71. Laybutt DR, Schmitz-peiffer C, Saha AK, Ruderman NB, Biden TJ, Kraegen EW. Muscle lipid accumulation and protein kinase C activation in the insulin-resistant chronically glucose-infused rat. AmJ Physiol 1999;277:E1070-E1076.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GlaxoSmithKline, New Frontiers Science Park North, Coldharbour Road, Harlow, Essex, CM19 5AD, UK

    Jonathan R. S. Arch

Authors
  1. Jonathan R. S. Arch
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arch, J.R.S. The β3-Adrenergic System and β3-Adrenergic Agonists. Rev Endocr Metab Disord 2, 385–393 (2001). https://doi.org/10.1023/A:1011852500209

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011852500209

Search

Navigation